Advances in neurointensive care

Annals of the Academy of Medicine Singapore

Volumn 30, Issue 3, 2001, Pages 300-309

  Chua, Hoe Chin ^a   Lew, T W K ^b   Ng, P Y ^b   Yeo, T T ^b  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b NONE

Author keywords

Guillain Barre syndrome; Head injury; Intracerebral haemorrhage; Ischaemic stroke; Myasthenic crisis; Status epilepticus; Subarachnoid haemorrhage

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CLOMETHIAZOLE; DIAZEPAM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ISOFLURANE; LIDOCAINE; LORAZEPAM; MANNITOL; METHYLPREDNISOLONE; MIDAZOLAM; NEUROPROTECTIVE AGENT; NIMODIPINE; PAPAVERINE; PARALDEHYDE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PROPOFOL; STEROID; SUXAMETHONIUM; TIRILAZAD; TISSUE PLASMINOGEN ACTIVATOR; VALPROIC ACID;

ARTIFICIAL EMBOLISM; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDUCED DISEASE; EPILEPTIC STATE; GUILLAIN BARRE SYNDROME; HEAD INJURY; HEALTH CARE DELIVERY; HUMAN; HYPERVENTILATION; INTENSIVE CARE; MEDICAL SPECIALIST; MYASTHENIA; NEUROLOGIC DISEASE; NEUROSURGERY; PATHOPHYSIOLOGY; PATIENT CARE; PLASMAPHERESIS; PRACTICE GUIDELINE; SKILL; STROKE; SUBARACHNOID HEMORRHAGE; TRAUMATIC EPILEPSY;

EID: 0034868221     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (110)

1. Lew T W K, Darby J M. Central nervous system. In: Shoemaker W, Ayres S M, Grenvik A N A, Holbrook P R, editors. Pocket Companion to Textbook of Critical Care. Philadelphia: WB Saunders Co, 1996: 564-612.
2. Young M P, Birkmeyer J D. Potential reduction in mortality rates using an intensivist model to manage intensive care units. Eff Clin Pract 2000; 3:284-9.
3. Hanson C W, Deutschman C S, Anderson H L, Reilly P M, Behringer E C, Schwab C W, et al. Effects of an organized critical care service on outcomes and resource utilization: a cohort study. Crit Care Med 1999; 27:270-4.
4. Carlson R W, Weiland D E, Srivathsan K. Does a full-time. 24-hour intensivist improve care and efficiency? Crit Care Clin 1996; 12: 525-51.
5. Milzman D P, Hinson D, Magnant C M. Overview and outcomes. Crit Care Clin 1993; 9:633-56.
6. Obrist W D, Langfitt T W, Jaggi J L, Cruz J, Gennarelli T A. Cerebral blood flow and metabolism in comatose patients with acute head injury. Relationship to intracranial hypertension. J Neurosurg 1984; 61:241-53.
7. Bouma G J, Muizelaar J P, Choi S C, Newlon P G, Young H F. Cerebral circulation and metabolism after severe traumatic brain injury: The elusive role of ischemia. J Neurosurg 1991; 75:685-93.
8. Kotapka M J, Graham D I, Adam J H, Gennarelli T A. Hippocampal pathology in fatal human brain injury without intracranial pressure. J Neurotrauma 1994; 11:317-24.
9. Lipton S A, Rosenberg P A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-22.
10. MacManus J P, Hill I E, Huang Z G, Rasquinha I, Xue D, Buchan A M. DNA damage consistent with apoptosis in transient ischaemic neocortex. Neuroreport 1994; 5:493-6.
11. Ng I, Yeo T T, Tang W Y, Soong R, Ng P Y, Smith D R, et al. Apoptosis occurs after cerebral contusions in humans. Neurosurgery 2000; 46: 949-56.
12. Chestnut R M, Marshall L F, Klauber M R. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993; 34:216-22.
13. Powers W J. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology 1993; 43:461-7.
14. Suarez J I, Qureshi A I, Bhardwaj A, Williams M A, Schnitzer M S, Mirski M, et al. Treatment of refractory intracranial hypertension with 23.4% saline. Crit Care Med 1998; 26:1118-23.
15. Rapp R P, Young B, Twyman D, Bivins B A, Haack D, Tibbs P A, et al. The favourable effect of early parenteral feeding on survival in head-injured patients. J Neurosurg 1983; 58:906-12.
16. Young B, Ott L, Kasarkis E. Zinc supplementation is associated with improved neurological recovery rate and visceral protein levels of patients with severe closed head injury. J Neurotrauma 1996; 13:25-34.
17. Smith J Jr, Martin L F, Young W W, Macioce D P. Do trauma centers improve outcome over non-trauma centers? J Trauma 1990; 30: 1533-8.
18. Ng I, Lew T W K, Yeo T T, Ong P L, Tan K K, Seow W T, et al. Outcome of patients with traumatic brain injury managed on a standardized head injury protocol. Ann Acad Med Singapore 1998; 27:332-9.
19. Rosner M J, Daughton S. Cerebral perfusion pressure management on head injured patients. J Trauma 1990; 30:933-40.
20. Cruz J. The first decade of continuous monitoring of jugular bulb oxyhemoglobin saturation: management strategies and clinical outcome. Crit Care Med 1998; 26:344-51.
21. Marshall L F, Gautille T, Klauber M R, Marshall L F. The outcome of severe closed head injury. J Neurosurg 1991: 75(Suppl)1: S287-92.
22. Jaggi J L, Obrist W D, Gennarelli T A. Relationship of early cerebral blood flow and metabolism to outcome in acute head injury. J Neurosurg 1990; 72:176-82.
23. Chesnut R M. Hyperventilation versus cerebral perfusion pressure management: Time to change the question. Crit Care Med 1998; 26:210-2.
24. Chan K, Miller J D, Dearden N M, Andrews P J D, Midgley S. The effects of changes in cerebral perfusion pressure upon middle cerebral artery blood flow velocity and jugular venous oxygen saturation after severe brain injury. J Neurosurg 1992; 77:55-61.
25. Ng I, Wong A, Lew T W K, Yeo T T. Correlation of favourable patient outcome in a standardised head injury management protocol to the level of cerebral perfusion pressure achieved. Crit Care Med 1997; 25:A74.
26. Cormio M, Valadka A B, Robertson C S. Elevated jugular venous oxygen saturation after severe head injury. J Neurosurg 1999; 90:9-15.
27. Gopinath S P, Robertson C S, Contant C F, Hayes C, Feldman Z, Narayan R K, et al. Jugular venous desaturation and outcome after head injury. J Neurol Neurosurg Psych 1994; 57:717-23.
28. Polin R S, Shaffrey M E, Bogaev C A, Tisdale N, Germanson T, Bocchicchio B, et al. Decompressive bifrontal craniectomy in the treatment of severe refractory posttraumatic cerebral edema. Neurosurgery 1997; 41:84-92.
29. Asgeirsson B, Grande P O, Nordstrom C H. A new therapy of posttrauma brain oedema based on haemodynamic principles for brain volume regulation. Intensive Care Med 1994; 20:260-7.
30. Eker C, Asgeirsson B, Grande P O, Schalen W, Nordstrom C H. Improved outcome after severe head injury with a new therapy based on principles for brain volume regulation and preserved microcirculation. Crit Care Med 1998; 26:1881-7.
31. Marion D W, Penrod L E, Kelsey S F, Obrist W D, Kochanek P M, Palmer A M, et al. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med 1997; 336:540-6.
32. Harders A. Kakarieka A. Braakman R. Traumatic subarachnoid haemorrhage and its treatment with nimodipine. J Neurosurg 1996; 85:82-9.
33. Sarti C, Tuomilehto J, Salomaa V, Sivenius J, Kaarsalo E, Narva E V, et al. Epidemiology of subarachnoid hemorrhage in Finland from 1983 to 1985. Stroke 1991; 22:848-53.
34. Lai S H, Lau G, Chao T C. Berry aneurysms: a cross-sectional study of 105 autopsy cases recorded between 1982 and 1996 [abstract]. Abstract Handbook of the 32nd Singapore-Malaysia Congress of Medicine; 1998 August 13-16; Singapore. Singapore: Academy of Medicine, Singapore, 1998:397.
35. Locksley H B. Report on the cooperative study of intracranial aneurysms and subarachnoid haemorrhage. In: Sahs A L, Perret G E, Locksley H B, editors. Intracranial Aneurysms and Subarachnoid Haemorrhage. Philadelphia: JB Lippincott, 1969:219-368.
36. Mayberg M R, Batjer H H, Dacey R, Diringer M, Haley C, Heros R C, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke 1994; 25:2315-28.
37. Kassell N F, Torner J C. Aneurysmal rebleeding: a preliminary report from the Cooperative Aneurysm Study. Neurosurgery 1983; 13:479-81.
38. Friedman A H. Timing of aneurysm surgery. In: Wilkins R H, Rengachary S S, editors. Neurosurgery. 2nd ed. USA: McGraw Hill Inc., 1996: 2255-60.
39. Kassell N F, Torner J C, Haley E C Jr, Jane J A, Adams H P, Kongable G L. The international cooperative study on the timing of aneurysm surgery. J Neurosurg 1990; 73:18-47.
40. Weir B, Findlay J M. Subarachnoid hemorrhage. In: Carter L P, Spetzler R F, editors. Neurovascular Surgery. USA: McGraw Hill Inc., 1995:557-81.
41. Eskridge J M, Song J K. Endovascular embolisation of 150 basilar tip aneurysms with GDC coils: results of FDA multicentre clinical trial. J Neurosurg 1998; 89:81-6.
42. Weir B, Grace M, Hansen J. Time course of vasospasm in man. Neurosurgery 1978; 48:173-8.
43. Eskridge J M, McAuliffe W, Song J K, Deliganis A V, Newell D W, Lewis D H, et al. Balloon angioplasty for the treatment of vasospasm: results of first 50 cases. Neurosurgery 1998; 42:510-7.
44. Polin R S, Hansen C A, German P, Chadduck J B, Kassell N F. Intraarterially administered papaverine for the treatment of symptomatic cerebral vasospasm. Neurosurgery 1998; 42:1256-67.
45. th Annual Scientific Meeting; 1998 Nov 7; Singapore. Singapore: Tan Tock Seng Hospital, 1998:13.
46. Venketasubramaniam N, Sadasivan B, Tan A K Y. Stroke patterns in a Singapore hospital based stroke data bank. Cerebrovasc Dis 1994; 4:250.
47. Broderick J P, Adams H P Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, et al. Guidelines for the management of healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke 1999; 30:905-15.
48. Hankey G J, Hon C. Surgery for primary intracerebral haemorrhage: is it safe and effective? Stroke 1997; 28:2126-32.
49. Morgenstern L B, Frankowski R F, Shedden P, Pasteur W, Grotta J C. Surgical treatment for intracerebral haemorrhage. A single centre randomized clinical trial. Neurology 1998; 51:1359-63.
50. Bone R C. Treatment of convulsive status epilepticus. JAMA 1993; 270:854-9.
51. Lowenstein D H, Bleck T, Macdonald R L. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40:120-2.
52. st Annual Meeting; 1999 April 17-24; Toronto, Ontario, Canada. 4:7DS.001.
53. DeLorenzo R J, Garnett L K, Towne A R, Waterhouse E J, Boggs J G, Morton L, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia 1999; 40: 164-9.
54. Lowenstein D H, Alldredge B K. Status epilepticus. N Engl J Med 1998; 14:970-6.
55. Leppik I E, Derivan A T, Homan R W, Walker J, Ramsay R E, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249:1452-4.
56. Browne T R, Kugler A R, Eldon M A. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996; 46(Suppl 1):S3-S7.
57. Leppik I E, Boucher B A, Wilder B J, Murthy V S, Watridge C, Graves N M, et al. Pharmacokinetics and safety of a phenytoin prodrug given IM or IV in patients. Neurology 1990; 40(3 part 1):456-60.
58. Shorvon S. Status epilepticus: Its clinical features and treatment in children and adults. Cambridge: Cambridge Univ Press, 1994.
59. Young G B, Blume W T, Bolton C F, Warren K G. Anesthetic barbiturates in refractory status epilepticus. Can J Neurol Sci 1980; 7:291-2.
60. Partinen M, Kovanen J, Nilsson E. Status epilepticus treated by barbiturate anaesthesia with continuous monitoring of cerebral function. Br Med J (Clin Res Ed) 1981; 282:520-1.
61. Orlowski J P, Erenberg G, Lueders H, Cruse R P. Hypothermia and barbiturate coma for refractory status epilepticus. Crit Care Med 1984; 12:367-72.
62. Rashkin M C, Youngs C, Penovich P. Pentobarbital treatment of refractory status epilepticus. Neurology 1987; 37:500-3.
63. Lowenstein D H, Aminoff M J, Simon R P. Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients. Neurology 1988; 38:395-400.
64. Crawford T O, Mitchell W G, Fishman L S, Snodgrass S R. Very-high-dose phenobarbital for refractory status epilepticus in children. Neurology 1988; 38:1035-40.
65. Osorio I, Reed R C. Treatment of refractory generalized tonic-clonic status epilepticus with pentobarbital anesthesia after high-dose phenytoin. Epilepsia 1989; 30:464-71.
66. Van Ness P C. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia 1990; 31:61-7.
67. Yaffe K, Lowenstein D H. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993; 43:895-900.
68. Krishnamurthy K B, Drislane F W. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia 1999; 40:759-62.
69. Chua H C, Tan A K Y, Tan C B, Tjia H. High dose phenobarbitone for status epilepticus. Neurol J Southeast Asia 1999; 4:25-9.
70. Giroud M, Gras D, Escousse A, Dumas R, Venaud G. Use of injectable valproic acid in status epilepticus. A pilot study. Drug Invest 1993; 5:154-9.
71. Price D J. Intravenous valproate: experience in neurosurgery. R Soc Med Int Congr Symp Ser 1989; 152:197-203.
72. Moore A J, Bell B A, Berry D J. Intravenous sodium valproate in neurosurgery: repeat dose pharmacokinetic study and safety assessment in neurosurgical patients. R Soc Med Int Congr Symp Ser 1989; 152:204-7.
73. Kaplan P W. Intravenous valproate treatment of generalized nonconvulsive status epilepticus. Clin Electroencephalogr 1999; 30: 1-4.
74. Fulton B, Park G R. Intravenous chlormethiazole. Br J Hosp Med 1992; 48:742-7.
75. Hanley D F Jr, Pozo M. Treatment of status epilepticus with midazolam in the critical care setting. Int J Clin Pract 2000; 54:30-5.
76. Fountain N B, Adams R E. Midazolam treatment of acute and refractory status epilepticus. Clin Neuropharmacol 1999; 22:261-7.
77. Bleck T P. Management approaches to prolonged seizures and status epilepticus. Epilepsia 1999; 40(Suppl 1):S59-63.
78. Labar D R, Ali A, Root J. High-dose intravenous lorazepam for the treatment of refractory status epilepticus. Neurology 1994; 44:1400-3.
79. Brown L A, Levin G M. Role of propofol in refractory status epilepticus. Ann Pharmacother 1998; 32:1053-9.
80. Wijdicks E F M. The clinical practice of critical care neurology. Philadelphia: Lippincott-Raven Publishers, 1997:279-89.
81. Thomas C E, Mayer S A, Gungor Y, Swarup R, Webster E A, Chang I, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48:1253-60.
82. Grob D, Arsura E L, Brunner N G, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505:472-99.
83. rd ed. Philadelphia: Lippincott-Raven Publishers, 1997:2005-16.
84. rd ed. New York: Raven Press, 1993:351-62.
85. Qureshi A I, Choudhry M A, Akbar M S, Mohammad Y, Chua H C, Yahia A M, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52:629-32.
86. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41:789-96.
87. Kornfeld P, Ambinder E P, Mittag T, Bender A N, Papatestas A E, Goldberg J, et al. Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 1981; 38:478-81.
88. Arsura E L, Brunner N G, Namba T. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985; 42: 1149-53.
89. Ropper A H, Wijdicks E F M. Blood pressure fluctuations in the dysautonomia of Guillain-Barre syndrome. Arch Neurol 1990; 47: 706-8.
90. Frison J C, Sanchez L, Garnacho A, Bofill J, Olivero R, Miquel C. Heart rate variations in Guillain-Barre syndrome. BMJ 1980; 281:649.
91. Ferraro-Herrera A S, Kern H B, Nagler W. Autonomie dysfunction as the presenting feature of Guillain-Barre syndrome. Arch Phys Med Rehabil 1997; 78:777-9.
92. Greenland P, Griggs R C. Arrhythmic complications in the Guillain-Barre syndrome. Arch Intern Med 1980; 140:1053-5.
93. The Guillain-Barre Syndrome Study Group. Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985; 35:1096-104.
94. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-61.
95. Van der Meche F G, Schmitz P I, and the Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992; 326:1123-9.
96. Castro L H, Ropper A H. Human immune globulin infusion in Guillain-Barre syndrome:worsening during and after treatment. Neurology 1993; 43:1034-6.
97. Kleyweg R P, Van der Meche F G A. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma exchange. J Neurol Neurosurg Psychiatry 1991; 54:957-60.
98. Hacke W, Schwab S, De Georgia M. Intensive care of acute ischemic stroke. Cerebrovasc Dis 1994; 4:385-92.
99. Hund E, Grau A, Hacke W. Neurocritical care for acute ischemic stroke. Neurosurg Clin N Am 1997; 8:271-82.
100. National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for the treatment of acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
101. Albers G W. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke 1999; 30:2230-7.
102. Schlaug G, Benfield A, Baird A E, Siewert B, Lovblad K O, Parker R A. et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 1999; 53:1528-37.
103. Barber P A, Darby D G, Desmond P M, Yang Q, Gerraty R P, Jolley D, et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology 1998; 51:418-26.
104. Li F, Carano R A, Irie K, Tatlisumak T, Silva M D, Pschorni U, et al. Neuroprotective effects of a novel broad-spectrum cation channel blocker, LOE 908 MS, on experimental focal ischemia: a multispectral study. J Magn Reson Imaging 1999; 10:138-45.
105. Lindsberg P J, Roine R O, Tatlisumak T, Sairanen T, Kaste M. The future of stroke treatment. Neurol Clin 2000; 18:495-510.
106. Muir K W, Grosset D G. Neuroprotection for acute stroke: making clinical trials work. Stroke 1999; 30:180-2.
107. Heiss W D, Thiel A, Grond M, Graf R. Which targets are relevant for therapy of acute ischemic stroke? Stroke 1999; 30:1486-9.
108. Chua H C, Ng P Y. Neuroprotection in acute stroke. Ann Acad Med Singapore 2001; 30:134-42.
109. Ropper A H, Shafran B. Brain edema after stroke: clinical syndrome and intracranial pressure. Arch Neurol 1984; 41:26-9.
110. Rosner M J. Pathophysiology and management of increased intracranial pressure. In: Andrews B T, editor. Neurosurgical Intensive Care. New York: McGraw-Hill Book Co, 1993:57-112.